Weijia Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weijia Xie has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Yafei Li
Department of Epidemiology, College of Preventive Medicine, Army Medical University, Chongqing, China
12 shared publications - Chengying Li
Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, People’s Republic of China
11 shared publications - Li Bai
State Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
11 shared publications - Meiyu Zhou
Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, People’s Republic of China
11 shared publications - Menglei Chen
Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, People’s Republic of China
11 shared publications - Na Wu
Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, People’s Republic of China
11 shared publications
Latest Publications
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
Primers and RNA oligonucleotides sequences used in this study.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
Primers and RNA oligonucleotides sequences used in this study.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The expression of YTHDC1 level in shNC and shYTHDC1 in A549 and H1299 cells, detected by qRT-PCR and western blotting.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The expression of YTHDC1 level in shNC and shYTHDC1 in A549 and H1299 cells, detected by qRT-PCR and western blotting.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The gene expression correlations between SFTA1P and downstream target genes of TGF-β signaling pathway.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The gene expression correlations between SFTA1P and downstream target genes of TGF-β signaling pathway.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The protein expression of E-cadherin and Vimentin were evaluated by WB in H1299 cells after treated with siRNA targeting SFTA1P and BAY-1143572 (1μM).
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The protein expression of E-cadherin and Vimentin were evaluated by WB in H1299 cells after treated with siRNA targeting SFTA1P and BAY-1143572 (1μM).
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Data from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
SFTA1P is a pseudogene-derived long noncoding RNA and has become a master regulator in tumor carcinogenesis and progression processes. SFTA1P has been reported as a potential diagnostic and prognostic biomarker in non–small cell lung cancer (NSCLC). The downregulation of SFTA1P in tumor tissue has been associated with poor prognosis; however, the detailed molecular mechanism and biological functions still need to be investigated. We demonstrated that SFTA1P inhibited the growth and metastasis of NSCLC in vitro and in vivo. SFTA1P had dual functions in the cytoplasm and nucleus: In the cytoplasm, SFTA1P can serve as a “sponge” for miR-665 to increase the expression level of TGFBR2; in the nucleus, SFTA1P can bind the positive transcription elongation factor b and subsequently inhibit the transcriptase activity of RNA polymerase II. The regulation of TGFBR2 and positive transcription elongation factor b via SFTA1P depends on its subcellular localization, which was affected by the status of the N6-methyladenosine RNA modification of SFTA1P. Our research demonstrated that the candidate tumor-suppressor SFTA1P is extensively involved in NSCLC, which may offer novel insights into NSCLC oncogenesis.Implications:SFTA1P is downregulated in NSCLC and had dual functions in the cytoplasm and nucleus.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
SFTA1P is a pseudogene-derived long noncoding RNA and has become a master regulator in tumor carcinogenesis and progression processes. SFTA1P has been reported as a potential diagnostic and prognostic biomarker in non–small cell lung cancer (NSCLC). The downregulation of SFTA1P in tumor tissue has been associated with poor prognosis; however, the detailed molecular mechanism and biological functions still need to be investigated. We demonstrated that SFTA1P inhibited the growth and metastasis of NSCLC in vitro and in vivo. SFTA1P had dual functions in the cytoplasm and nucleus: In the cytoplasm, SFTA1P can serve as a “sponge” for miR-665 to increase the expression level of TGFBR2; in the nucleus, SFTA1P can bind the positive transcription elongation factor b and subsequently inhibit the transcriptase activity of RNA polymerase II. The regulation of TGFBR2 and positive transcription elongation factor b via SFTA1P depends on its subcellular localization, which was affected by the status of the N6-methyladenosine RNA modification of SFTA1P. Our research demonstrated that the candidate tumor-suppressor SFTA1P is extensively involved in NSCLC, which may offer novel insights into NSCLC oncogenesis.Implications:SFTA1P is downregulated in NSCLC and had dual functions in the cytoplasm and nucleus.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The expression patterns and subcellular localization of SFTA1P in lung cancer cell lines.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The expression patterns and subcellular localization of SFTA1P in lung cancer cell lines.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
Tumor volume of AAV-SFTA1P and AAV-NC treatment group
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
Tumor volume of AAV-SFTA1P and AAV-NC treatment group
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The relationship of TGFBR2, PI3K−Akt signaling pathway protein expression levels and SFTA1P
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The relationship of TGFBR2, PI3K−Akt signaling pathway protein expression levels and SFTA1P
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
Effects of SFTA1P on lung squamous cell carcinoma cell proliferation, apoptosis, and migration in vitro
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
Effects of SFTA1P on lung squamous cell carcinoma cell proliferation, apoptosis, and migration in vitro
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The m6A RNA modification sites in SFTA1P sequence identified by using SRAMP prediction server (http://www.cuilab.cn/sramp)
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The m6A RNA modification sites in SFTA1P sequence identified by using SRAMP prediction server (http://www.cuilab.cn/sramp)